Investor Hub

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases.

Latest investor presentation
Latest clinical presentation
Latest quarterly earnings
Annual report
Global ticker
NASDAQNVAX

SEC

Access filings by selecting the date range and type using the drop-down menus.

NASDAQNVAX
FormDescriptionDateFormat
10-QQuarterly report which provides a continuing view of a company's financial positionNov 14, 1997Open Quarterly report which provides a continuing view of a company's financial position in HTML.Open Quarterly report which provides a continuing view of a company's financial position in DOC file.Open Quarterly report which provides a continuing view of a company's financial position in PDF file.Open Quarterly report which provides a continuing view of a company's financial position in XLS file.
10-QQuarterly report which provides a continuing view of a company's financial positionAug 12, 1997Open Quarterly report which provides a continuing view of a company's financial position in HTML.Open Quarterly report which provides a continuing view of a company's financial position in DOC file.Open Quarterly report which provides a continuing view of a company's financial position in PDF file.Open Quarterly report which provides a continuing view of a company's financial position in XLS file.
10-QQuarterly report which provides a continuing view of a company's financial positionMay 9, 1997Open Quarterly report which provides a continuing view of a company's financial position in HTML.Open Quarterly report which provides a continuing view of a company's financial position in DOC file.Open Quarterly report which provides a continuing view of a company's financial position in PDF file.Open Quarterly report which provides a continuing view of a company's financial position in XLS file.
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsApr 30, 1997Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in HTML.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in DOC file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in PDF file.Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in XLS file.
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Apr 1, 1997Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in HTML.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in DOC file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in PDF file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in XLS file.
SC 13DFiling by person(s) reporting owned shares of common stock in a public company >5%Mar 26, 1997Open Filing by person(s) reporting owned shares of common stock in a public company >5% in HTML.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in DOC file.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in PDF file.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in XLS file.
10-KAnnual report which provides a comprehensive overview of the company for the past yearMar 21, 1997Open Annual report which provides a comprehensive overview of the company for the past year in HTML.Open Annual report which provides a comprehensive overview of the company for the past year in DOC file.Open Annual report which provides a comprehensive overview of the company for the past year in PDF file.Open Annual report which provides a comprehensive overview of the company for the past year in XLS file.
SC 13G/AAmendment to a previously filed SC 13GMar 13, 1997Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.
S-3Simplified registration formMar 4, 1997Open Simplified registration form in HTML.Open Simplified registration form in DOC file.Open Simplified registration form in PDF file.Open Simplified registration form in XLS file.
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.